ATE447573T1 - Chinoxalinyl-makrocyclische hepatitis c serin protease-hemmer - Google Patents

Chinoxalinyl-makrocyclische hepatitis c serin protease-hemmer

Info

Publication number
ATE447573T1
ATE447573T1 AT04750236T AT04750236T ATE447573T1 AT E447573 T1 ATE447573 T1 AT E447573T1 AT 04750236 T AT04750236 T AT 04750236T AT 04750236 T AT04750236 T AT 04750236T AT E447573 T1 ATE447573 T1 AT E447573T1
Authority
AT
Austria
Prior art keywords
present
compounds
serine protease
hepatitis
formula
Prior art date
Application number
AT04750236T
Other languages
English (en)
Inventor
Suanne Nakajima
Ying Sun
Datong Tang
Gouyou Xu
Brian Porter
Yat OR
Zhe Wang
Zhenwei Miao
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Application granted granted Critical
Publication of ATE447573T1 publication Critical patent/ATE447573T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AT04750236T 2003-04-18 2004-04-16 Chinoxalinyl-makrocyclische hepatitis c serin protease-hemmer ATE447573T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41875903A 2003-04-18 2003-04-18
PCT/US2004/011841 WO2004093798A2 (en) 2003-04-18 2004-04-16 Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors

Publications (1)

Publication Number Publication Date
ATE447573T1 true ATE447573T1 (de) 2009-11-15

Family

ID=33309537

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04750236T ATE447573T1 (de) 2003-04-18 2004-04-16 Chinoxalinyl-makrocyclische hepatitis c serin protease-hemmer

Country Status (16)

Country Link
EP (2) EP2143727B1 (de)
JP (2) JP4778893B2 (de)
KR (1) KR101031825B1 (de)
CN (1) CN1788006A (de)
AT (1) ATE447573T1 (de)
AU (2) AU2004231987C1 (de)
CA (1) CA2522561C (de)
CY (1) CY1109748T1 (de)
DE (1) DE602004023924D1 (de)
DK (1) DK1615613T3 (de)
ES (2) ES2335887T3 (de)
HK (2) HK1083337A1 (de)
PL (1) PL1615613T3 (de)
PT (1) PT1615613E (de)
SI (1) SI1615613T1 (de)
WO (1) WO2004093798A2 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2004276281A1 (en) * 2003-09-26 2005-04-07 Schering Corporation Macrocyclic inhibitors of hepatitis C virus NS3 serine protease
WO2005073216A2 (en) 2004-01-30 2005-08-11 Medivir Ab Hcv ns-3 serine protease inhibitors
US7683033B2 (en) 2004-02-04 2010-03-23 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
SI1718608T1 (sl) 2004-02-20 2013-11-29 Boehringer Ingelheim International Gmbh Inhibitorji virusne polimeraze
BRPI0517463A (pt) * 2004-10-21 2008-10-07 Pfizer inibidores da protease do vìrus da hepatite c, composições e tratamentos usando os mesmos
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5249028B2 (ja) * 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US8076365B2 (en) 2005-08-12 2011-12-13 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US20070281884A1 (en) * 2006-06-06 2007-12-06 Ying Sun Macrocyclic oximyl hepatitis C protease inhibitors
UY30437A1 (es) * 2006-06-26 2008-01-31 Enanta Pharm Inc Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
WO2008008776A2 (en) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2008019477A1 (en) 2006-08-17 2008-02-21 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US20080107623A1 (en) * 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101568543B (zh) * 2006-11-16 2012-06-06 百时美施贵宝公司 大环肽作为丙型肝炎病毒抑制剂
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA200900969A1 (ru) * 2007-01-08 2010-02-26 Феномикс Корпорейшн Макроциклические ингибиторы протеазы гепатита с
AU2008271116B2 (en) * 2007-06-29 2012-09-20 Gilead Sciences, Inc. Antiviral compounds
US20090047252A1 (en) * 2007-06-29 2009-02-19 Gilead Sciences, Inc. Antiviral compounds
EP2162432A2 (de) 2007-06-29 2010-03-17 Gilead Sciences, Inc. Antivirale verbindungen
EP2188274A4 (de) 2007-08-03 2011-05-25 Boehringer Ingelheim Int Virale polymerasehemmer
CA2708150A1 (en) 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Fluorinated tripeptide hcv serine protease inhibitors
JP5623289B2 (ja) 2007-12-19 2014-11-12 ベーリンガーインゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼインヒビター
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
RU2490272C2 (ru) * 2008-02-04 2013-08-20 Айденикс Фармасьютикалз, Инк. Макроциклические ингибиторы серинпротеазы
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009148923A1 (en) 2008-05-29 2009-12-10 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
AU2012201327B2 (en) * 2008-09-11 2014-06-26 Abbvie Ireland Unlimited Company Macrocyclic hepatitis C serine protease inhibitors
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102271699A (zh) 2009-01-07 2011-12-07 西尼克斯公司 用于治疗hcv和hiv感染的环孢菌素衍生物
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
MX2011012155A (es) 2009-05-13 2012-02-28 Enanta Pharm Inc Compuestos macrociclicos como inhibidores del virus de hepatitis c.
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
EP2461811B1 (de) 2009-08-05 2016-04-20 Idenix Pharmaceuticals LLC. Makrocyclische serinproteasehemmer gegen virale infektionen, im besonderen hvc
AU2010298028A1 (en) * 2009-09-28 2012-04-19 Intermune, Inc. Cyclic peptide inhibitors of hepatitis C virus replication
HUE028384T2 (en) 2010-09-21 2016-12-28 Enanta Pharm Inc HCV serine protease inhibitors derived from macrocyclic proline
US20120101032A1 (en) * 2010-10-22 2012-04-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
EP2658858A4 (de) 2010-12-30 2014-06-25 Enanta Pharm Inc Makrocyclische hepatitis-c-serinprotease-hemmer mit phenanthridin
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
KR20150074051A (ko) 2012-10-19 2015-07-01 브리스톨-마이어스 스큅 컴퍼니 C형 간염 바이러스 억제제
EP2914613B1 (de) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Inhibitoren des hepatitis-c-virus
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2943496B1 (de) * 2013-01-10 2017-09-06 Bristol-Myers Squibb Company Makrocyclische benzofuran- und azabenzofuranverbindungen zur behandlung von hepatitis c
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
CA3085079A1 (en) 2013-03-13 2014-10-02 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof
CN105073758B (zh) 2013-03-15 2017-08-11 吉利德科学公司 丙型肝炎病毒抑制剂
AU2014278005B2 (en) 2013-06-14 2018-11-22 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
EP3089757A1 (de) 2014-01-03 2016-11-09 AbbVie Inc. Feste antivirale darreichungsformen
EP2899207A1 (de) 2014-01-28 2015-07-29 Amikana.Biologics Neues Verfahren zum Testen von HCV-Proteasehemmung
AU2017214557B2 (en) 2016-02-04 2022-05-19 The Johns Hopkins University Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
CA3013783A1 (en) 2016-02-04 2017-08-10 The Johns Hopkins University Rapaglutins, novel inhibitors of glut and use thereof
KR20200064075A (ko) 2017-09-07 2020-06-05 포그 파마슈티컬스 인코포레이티드 베타-카테닌 기능을 조절하는 제제 및 이의 방법
US20220372014A1 (en) * 2019-10-01 2022-11-24 The Johns Hopkins University Neuroprotective compounds and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013482A1 (en) * 1996-09-27 1998-04-02 Merck & Co., Inc. Detergent-free hepatitis c protease
US5861297A (en) 1996-09-27 1999-01-19 Merck & Co., Inc. Detergent-free hepatitis C protease
PT1003775E (pt) * 1997-08-11 2005-07-29 Boehringer Ingelheim Ca Ltd Peptidos inibidores da hepatite c
DE69934104T2 (de) 1998-03-31 2007-06-28 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von serinproteasen, insbesondere von hepatitis c virus ns3 protease
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6086469A (en) * 1998-10-29 2000-07-11 Dec International, Inc. Method and means for conveying and processing an extruded sausage strand
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition

Also Published As

Publication number Publication date
AU2010200619A1 (en) 2010-03-11
PL1615613T3 (pl) 2010-04-30
EP2143727B1 (de) 2015-01-21
CY1109748T1 (el) 2014-09-10
ES2335887T3 (es) 2010-04-06
HK1083337A1 (en) 2006-06-30
PT1615613E (pt) 2010-02-09
WO2004093798A3 (en) 2005-12-08
EP2143727A1 (de) 2010-01-13
ES2535147T3 (es) 2015-05-06
AU2004231987C1 (en) 2010-09-30
JP2011178781A (ja) 2011-09-15
WO2004093798A2 (en) 2004-11-04
AU2004231987A1 (en) 2004-11-04
AU2010200619B2 (en) 2013-11-07
CA2522561A1 (en) 2004-11-04
SI1615613T1 (sl) 2010-03-31
DE602004023924D1 (en) 2009-12-17
EP1615613B1 (de) 2009-11-04
DK1615613T3 (da) 2010-03-22
EP1615613A4 (de) 2007-02-14
EP1615613A2 (de) 2006-01-18
KR101031825B1 (ko) 2011-04-29
JP4778893B2 (ja) 2011-09-21
HK1140214A1 (en) 2010-10-08
CA2522561C (en) 2012-07-17
KR20050123170A (ko) 2005-12-29
AU2004231987B2 (en) 2009-11-19
CN1788006A (zh) 2006-06-14
JP2007525455A (ja) 2007-09-06

Similar Documents

Publication Publication Date Title
ATE447573T1 (de) Chinoxalinyl-makrocyclische hepatitis c serin protease-hemmer
WO2004113365A3 (en) Hepatitis c serine protease tri-peptide inhibitors
WO2008002924A3 (en) Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2005007681A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2004072243A3 (en) Macrocyclic hepatitis c serine protease inhibitors
HK1101402A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2005037860A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2007143694A3 (en) Macrocyclic oximyl hepatitis c protease inhibitors
MX2010006210A (es) Inhibidores de serina proteasa de hcv de tripeptido fluorado.
WO2009053828A3 (en) P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
MX2010006209A (es) Derivados de quinoxalinilo.
ATE349463T1 (de) Verbrückte bizyklische serinproteaseinhibitoren
WO2008022006A3 (en) Arylalkoxyl hepatitis c virus protease inhibitors
WO2008019303A3 (en) Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors
MX2010005262A (es) Compuestos que contienen quinoxalina como inhibidores del virus de hepatitis c.
WO2008019266A3 (en) Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
WO2008021960A3 (en) Triazolyl macrocyclic hepatitis c serine protease inhibitors
WO2005035525A3 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2008021956A3 (en) Acylaminoheteroaryl hepatitis c virus protease inhibitors
WO2008021871A3 (en) Triazolyl acyclic hepatitis c serine protease inhibitors
MX2010006518A (es) Inhibidores de serina proteasa de hepatitis c de oximil macrociclica.
MX2010010276A (es) Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c.
WO2008019289A3 (en) Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
WO2009076166A3 (en) Oximyl hcv serine protease inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1615613

Country of ref document: EP